KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Preferred Shares: 2013-2021

Historic Preferred Shares for Xenon Pharmaceuticals (XENE) over the last 4 years, with Dec 2021 value amounting to $7.7 million.

  • Xenon Pharmaceuticals' Preferred Shares changed negligibly% to $7.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $7.7 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $7.7 million for FY2021, which is negligibly% changed negligibly from last year.
  • Xenon Pharmaceuticals' Preferred Shares amounted to $7.7 million in Q4 2021, which was down 0.00% from $7.7 million recorded in Q3 2021.
  • In the past 5 years, Xenon Pharmaceuticals' Preferred Shares ranged from a high of $21.8 million in Q1 2018 and a low of $7.7 million during Q1 2019.
  • For the 3-year period, Xenon Pharmaceuticals' Preferred Shares averaged around $7.7 million, with its median value being $7.7 million (2021).
  • Data for Xenon Pharmaceuticals' Preferred Shares shows a maximum YoY slumped of 64.57% (in 2019) over the last 5 years.
  • Quarterly analysis of 4 years shows Xenon Pharmaceuticals' Preferred Shares stood at $11.9 million in 2018, then crashed by 35.20% to $7.7 million in 2019, then remained steady at $7.7 million in 2020, then remained steady at $7.7 million in 2021.
  • Its last three reported values are $7.7 million in Q4 2021, $7.7 million for Q3 2021, and $7.7 million during Q2 2021.